EW Edwards Lifesciences Corp Insider Trading

CVP Donald E Jr Bobo sells 23,145 EW shares at $86.42; stock near 52-week high; 0 of 5 prior same-ticker sells well-timed.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, sold 23,145 shares at $86.42, reducing holdings by 19.0% to 98,611 shares. The sale occurred near the 52-week high ($87.93), with the current price at $86.51 just 1.6% below peak. Edwards Lifesciences shows solid fundamentals (11.6% annual revenue growth, $380.7M net income on $1.6B quarterly revenue, P/E of 45.53), supporting valuations around these levels. Notably, across his five prior same-ticker trades, 0 of 5 sells showed negative 90-day returns (well-timed indicator for sell activity), suggesting a pattern of selling into strength rather than ahead of declines. While his cross-ticker track record shows a 37.50% well-timed rate on 8 sells, this ticker-specific history of selling at or near peaks without subsequent downside protection offers a less favorable signal for position conviction.

CVP Donald E Jr Bobo sold 17,968 shares at EW for $1,472,678.46 on 2026-05-15; reduces holdings 36.7%.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, executed 2 separate sales totaling 17,968 shares for $1,472,678.46 at a blended average price of $81.96 on 2026-05-15. The transaction represents a -36.7% reduction in his holdings, from 48,937 shares to 30,969 shares post-sale. At the time of the filing, the stock traded at $82.39, within its 52-week range of $72.30–$87.89 and -6.3% from the 52-week high. Edwards Lifesciences reported latest-quarter revenue of $1,648,600,000.00 and net income of $380,700,000.00, with annual revenue growth of +11.6% and a P/E of 43.36. The magnitude and composition of this sale—two distinct transactions executed the same day—warrant attention to the timing and context of his decision relative to the company's fundamentals and his own transaction history.

CEO Bernard Zovighian sells $4.9M in EW shares in multi-transaction filing; 11th open-market sale in 36 months, part of planned equity dispositions.

Bernard Zovighian, Edwards Lifesciences' CEO, executed a significant multi-leg equity transaction disposing of roughly $4.9 million in stock across several sales and gifts over two days in May. This marks his 10th and 11th open-market sales in the past three years—a consistent pattern of selling rather than buying, with only one prior open-market purchase recorded. The stock is trading well below its 52-week high, yet Zovighian chose to sell into this weakness rather than accumulate. His prior five sales at this ticker showed mixed timing results—four were poorly-timed exits where the stock rose afterward, and one was well-timed as shares declined—suggesting his sales have not historically caught major downturns. The company itself remains profitable with growing revenues, trading at a moderate valuation, so the sales do not appear to be driven by fundamental deterioration. The combination of his heavy reliance on equity dispositions over acquisitions, the current sale size relative to his holdings, and the weak price position raises questions about whether this represents ordinary portfolio management or a signal worth deeper investigation.